The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique ‘two-modes’ inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human α-thrombin:synthetic-variegin complex at 2.4 ？ resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants.
References
[1]
Huntington JA (2005) Molecular recognition mechanisms of thrombin. J Thromb Haemost 3: 1861–1872.
[2]
Bode W, Turk D, Karshikov A (1992) The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1: 426–471.
[3]
Rydel TJ, Tulinsky A, Bode W, Huber R (1991) Refined structure of the hirudin-thrombin complex. J Mol Biol 221: 583–601.
[4]
Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, et al. (1991) Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol 221: 1379–1393.
[5]
Huntington JA (2008) How Na+ activates thrombin–a review of the functional and structural data. Biol Chem 389: 1025–1035.
[6]
Lane DA, Philippou H, Huntington JA (2005) Directing thrombin. Blood 106: 2605–2612.
[7]
Koh CY, Kini RM (2008) Anticoagulants from hematophagous animals. Expert Rev Hematol 1: 135–139.
[8]
Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186: 240–259.
[9]
Gross PL, Weitz JI (2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28: 380–386.
[10]
Greinacher A, Warkentin TE (2008) The direct thrombin inhibitor hirudin. Thromb Haemost 99: 819–829.
[11]
Warkentin TE, Greinacher A, Koster A (2008) Bivalirudin. Thromb Haemost 99: 830–839.
[12]
Yeh RW, Jang IK (2006) Argatroban: update. Am Heart J 151: 1131–1138.
[13]
Eriksson BI, Smith H, Yasothan U, Kirkpatrick P (2008) Dabigatran etexilate. Nat Rev Drug Discov 7: 557–558.
[14]
Champagne DE (2004) Antihemostatic strategies of blood-feeding arthropods. Curr Drug Targets Cardiovasc Haematol Disord 4: 375–396.
[15]
Koh CY, Kini RM (2009) Molecular diversity of anticoagulants from haematophagous animals. Thromb Haemost 102: 437–453.
[16]
Koh CY, Kazimirova M, Trimnell A, Takac P, Labuda M, et al. (2007) Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick. J Biol Chem 282: 29101–29113.
[17]
Koh CY, Kazimirova M, Nuttall PA, Kini RM (2009) Noncompetitive inhibitor of thrombin. Chembiochem 10: 2155–2158.
[18]
Yonemura H, Imamura T, Soejima K, Nakahara Y, Morikawa W, et al. (2004) Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. J Biochem (Tokyo) 135: 577–582.
[19]
Soejima K, Mimura N, Yonemura H, Nakatake H, Imamura T, et al. (2001) An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin. J Biochem (Tokyo) 130: 269–277.
[20]
Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology 276: 307–326.
Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, et al. (1992) Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors. Biochemistry 31: 11689–11697.
[23]
Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
[24]
Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255.
[25]
Winn MD, Isupov MN, Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57: 122–133.
[26]
Laskowsi RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283–291.
[27]
Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375–W383.
[28]
Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774–797.
[29]
Bode W, Mayr I, Baumann U, Huber R, Stone SR, et al. (1989) The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8: 3467–3475.
[30]
Jagadeeswaran P, Paris R, Rao P (2006) Laser-induced thrombosis in zebrafish larvae: a novel genetic screening method for thrombosis. Methods Mol Med 129: 187–195.
[31]
Liu CC, Brustad E, Liu W, Schultz PG (2007) Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin. J Am Chem Soc 129: 10648–10649.
[32]
Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, et al. (1990) The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249: 277–280.
[33]
Page MJ, Macgillivray RT, Di Cera E (2005) Determinants of specificity in coagulation proteases. J Thromb Haemost 3: 2401–2408.
[34]
Perona JJ, Craik CS (1995) Structural basis of substrate specificity in the serine proteases. Protein Sci 4: 337–360.
[35]
Vindigni A, Dang QD, Di Cera E (1997) Site-specific dissection of substrate recognition by thrombin. Nat Biotechnol 15: 891–895.
[36]
Stone SR, Hofsteenge J (1986) Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25: 4622–4628.
[37]
Dodt J, Kohler S, Baici A (1988) Interaction of site specific hirudin variants with alpha-thrombin. FEBS Lett 229: 87–90.
[38]
Braun PJ, Dennis S, Hofsteenge J, Stone SR (1988) Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 27: 6517–6522.
[39]
Stone SR, Tapparelli C (1995) Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. J Enzyme Inhib 9: 3–15.
[40]
Fethiere J, Tsuda Y, Coulombe R, Konishi Y, Cygler M (1996) Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin. Protein Sci 5: 1174–1183.
[41]
Laskowski M Jr, Kato I (1980) Protein inhibitors of proteinases. Annu Rev Biochem 49: 593–626.
[42]
Slon-Usakiewicz JJ, Purisima E, Tsuda Y, Sulea T, Pedyczak A, et al. (1997) Nonpolar interactions of thrombin S′ subsites with its bivalent inhibitor: methyl scan of the inhibitor linker. Biochemistry 36: 13494–13502.
[43]
van de Locht A, Lamba D, Bauer M, Huber R, et al. (1995) Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J 14: 5149–5157.
[44]
van de Locht A, Stubbs MT, Bode W, Friedrich T, Bollschweiler C, et al. (1996) The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J 15: 6011–6017.
[45]
Macedo-Ribeiro S, Almeida C, Calisto BM, Friedrich T, Mentele R, et al. (2008) Isolation, cloning and structural characterisation of boophilin, a multifunctional Kunitz-type proteinase inhibitor from the cattle tick. PLoS ONE 3: e1624.
[46]
Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E (2007) Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A 104: 11603–11608.
[47]
Gandhi PS, Chen Z, Mathews FS, Di Cera E (2008) Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A 105: 1832–1837.
[48]
Martin PD, Robertson W, Turk D, Huber R, Bode W, et al. (1992) The structure of residues 7–16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem 267: 7911–7920.
[49]
Martin PD, Malkowski MG, DiMaio J, Konishi Y, Ni F, et al. (1996) Bovine thrombin complexed with an uncleavable analog of residues 7–19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1′, P2′, and P3′ substrate residues. Biochemistry 35: 13030–13039.
[50]
Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, et al. (1992) The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem 206: 187–195.
[51]
Gandhi PS, Chen Z, Di Cera E (2010) Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem 285: 15393–15398.
[52]
Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW (1992) Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 283(Pt 3): 737–743.
[53]
Matthews JH, Krishnan R, Costanzo MJ, Maryanoff BE, Tulinsky A (1996) Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1′ binding site. Biophys J 71: 2830–2839.
[54]
Slon-Usakiewicz JJ, Sivaraman J, Li Y, Cygler M, Konishi Y (2000) Design of P1′ and P3′ residues of trivalent thrombin inhibitors and their crystal structures. Biochemistry 39: 2384–2391.
[55]
Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW (1990) Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095–7101.
[56]
Fareed J, Jeske WP (2004) Small-molecule direct antithrombins: argatroban. Best Pract Res Clin Haematol 17: 127–138.
[57]
Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98: 155–162.
[58]
White CM (2005) Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J 149: S54–S60.
